Evidence map›Paper›PMID 33594359›Full record

ArticlebioRxiv : the preprint server for biology2021

Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses.

Jared Feldman, Julia Bals, Clara G Altomare, Kerri St Denis, Evan C Lam, Blake M Hauser, Larance Ronsard, Maya Sangesland, Thalia Bracamonte Moreno, Vintus Okonkwo and 5 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 12 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Jared Feldman *Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Julia Bals *Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Clara G AltomareDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Kerri St DenisRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Evan C LamRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Blake M HauserRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Larance RonsardRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Maya SangeslandRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Thalia Bracamonte MorenoRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Vintus OkonkwoRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Nathania HartojoRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Alejandro B BalazsRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Goran BajicDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Daniel LingwoodRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Aaron G SchmidtRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Ragon Institute of MGH, MIT and Harvard · USIcahn School of Medicine at Mount Sinai · USHarvard University · US

Funding

NCCAT: National Center for CryoEM Access and Training- Supplement for Windows 10 and FFIU24GM129539 · NIGMS · NEW YORK STRUCTURAL BIOLOGY CENTER · PI DE MARCO, ALEX, KIEFT, JEFFREY S · 2018 to 2023
$53.9M
MOLECULAR BASIS OF VIRAL INFECTIVITYT32AI007245 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Aaron Gregory Schmidt · 1985 to 2026
$11.3M
Epitope focusing to the receptor binding motif for a universal coronavirus vaccineR01AI146779 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI SCHMIDT, AARON GREGORY · 2019 to 2023
$4.2M
Innate-like BCR activity as a template for universal vaccination against influenza virusR01AI137057 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHACKERIAN, BRYCE C, LINGWOOD, DANIEL · 2018 to 2022
$2.6M
Engineering Humoral Immunity to Functionally Cure HIV InfectionDP2DA040254 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2015 to 2015
$2.6M
Defining and Exploiting a Genetic Template for an HIV VaccineDP2DA042422 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2016 to 2016
$2.6M
Triggering germline-encoded broadly neutralizing antibody responses against influenza virusR01AI153098 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BATISTA, FACUNDO DAMIAN, LINGWOOD, DANIEL · 2020 to 2023
$2.1M
CDRH3-independent B cell stimulation to selectively expand VRC01 lineages from a fully humanized immunoglobulin repertoireR01AI124378 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHACKERIAN, BRYCE C, LINGWOOD, DANIEL · 2017 to 2020
$2.0M
Systemic coordination of pro-inflammatory immune reactions through dendritic cell-restricted sIL6R biogenesisR01AI155447 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2021 to 2025
$2.0M
NIAID NIH HHS R01 AI124378NIAID NIH HHS R01 AI137057NIAID NIH HHS R01 AI146779NIAID NIH HHS R01 AI153098NIAID NIH HHS R01 AI155447NIAID NIH HHS T32 AI007245NIDA NIH HHS DP2 DA040254NIDA NIH HHS DP2 DA042422NIGMS NIH HHS U24 GM129539
6 · The paper itself

Abstract

Exposure to a pathogen elicits an adaptive immune response aimed to control and eradicate. Interrogating the abundance and specificity of the naive B cell repertoire contributes to understanding how to potentially elicit protective responses. Here, we isolated naive B cells from 8 seronegative human donors targeting the SARS-CoV-2 receptor-binding domain (RBD). Single B cell analysis showed diverse gene usage with no restricted complementarity determining region lengths. We show that recombinant antibodies engage SARS-CoV-2 RBD, circulating variants, and pre-emergent coronaviruses. Representative antibodies signal in a B cell activation assay and can be affinity matured through directed evolution. Structural analysis of a naive antibody in complex with spike shows a conserved mode of recognition shared with infection-induced antibodies. Lastly, both naive and affinity-matured antibodies can neutralize SARS-CoV-2. Understanding the naive repertoire may inform potential responses recognizing variants or emerging coronaviruses enabling the development of pan-coronavirus vaccines aimed at engaging germline responses.

Identifiers

PMID33594359
PMCPMC7885909
OpenAlexW3177846762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.